Researchers have developed a long-acting weekly injection that delivers steady doses of levodopa and carbidopa, potentially transforming care for Parkinson’s disease.

The acquisition of Avivia aligns with Ofichem’s broader merger and acquisition agenda and ongoing investment strategy.

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, potentially replacing the need for multiple daily tablets.

Varda Space Industries said on Thursday it has raised $187 million in a funding round led by venture capital firms Natural ...

“The CHMP’s positive opinion of our new tablet formulation of BRUKINSA is an important step toward bringing this thoughtful, patient-centered innovation to people facing certain B-cell cancers ...

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications Provided by Business Wire Jun 11, 2025, 1:05:00 PM ...

The tablet formulation can either be swallowed whole or dispersed in a teaspoon of filtered (non-chlorinated) water.

Viking previously reported positive results from a 28-day Phase 1 multiple ascending dose (MAD) clinical trial of the tablet formulation of VK2735 in healthy volunteers with a BMI ≥30.